Isotope technology firm Eckert & Ziegler is expanding its support for nuclear medicine-related drug development through a collaboration with Curasight.
Curasight is a spin-off company based on research by a group at the National University Hospital (Rigshospitalet) and University of Copenhagen in Denmark, and currently is seeking market clearance for its uPAR PET breast cancer diagnostic agent.
Eckert & Ziegler plans to help develop and validate the pharmaceutical production process through its isotope laboratories and global infrastructure. Preclinical and clinical trials will continue to be managed from Denmark.
In exchange for its services, Eckert & Ziegler will receive a minority interest in the venture.
